$161.30
1.68[1.05%]
At close: Apr 29
$159.60
-1.7000[-1.05%]
After Hours: 9:29AM EDT
Latest News for AbbVie Stock (NYSE:ABBV)
AbbVie Stock (NYSE: ABBV)
Categories: All
Monday, April 29, 2024
- Barclays Maintains Overweight on AbbVie, Lowers Price Target to $187Benzinga Newsdesk - 4 hours ago
- Peeling Back The Layers: Exploring AbbVie Through Analyst InsightsBenzinga Insights - 5 hours ago
- BMO Capital Maintains Outperform on AbbVie, Lowers Price Target to $180Benzinga Newsdesk - 6 hours ago
- Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This WeekShanthi Rexaline - 14 hours ago
Friday, April 26, 2024
- Arthritis Patients - Cigna's Evernorth To Offer Humira Biosimilar At No Out-of-Pocket CostVandana Singh - 3 days ago
- Tech Stocks Rebound As Magnificent 7 Roar On Strong Earnings, Energy Giants Tumble: What's Driving Markets Friday?Piero Cingari - 3 days ago
- AbbVie shares are trading lower, reversing from earlier strength on Q1 earnings.Benzinga Newsdesk - 3 days ago
- Ex-Humira Growth Platform Drives AbbVie's Q1 Performance, Drugmaker Lifts Annual Profit OutlookVandana Singh - 3 days ago
- AbbVie shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY24 adjusted EPS guidance above estimates.Benzinga Newsdesk - 3 days ago
- AbbVie Is Raising Its 2024 Adjusted EPS Guidance From $10.97-$11.17 To $11.13-$11.33, Which Includes An Unfavorable Impact Of $0.08 Per Share Related To Acquired IPR&D And Milestones Expense, Versus Consensus Of $11.12Benzinga Newsdesk - 3 days ago
- AbbVie Q1 2024 Adj EPS $2.31 Beats $2.23 Estimate, Sales $12.310B Beat $11.923B EstimateBenzinga Newsdesk - 3 days ago
- Wall Street Futures Ride High On Microsoft, Alphabet Cheer, But Will Inflation Data Burst The Bubble? Why This Analyst Thinks Bull Run Isn't Over YetShanthi Rexaline - 3 days ago
Thursday, April 25, 2024
- AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head StudyVandana Singh - 4 days ago
- AbbVie New Data Show RINVOQ Demonstrated Superiority Versus DUPIXENT Across Primary And All Secondary Endpoints In An Open-Label Head-To-Head Atopic Dermatitis Study; Achieved Both A 90% Or Greater Reduction In Eczema Area And Severity Index And A Worst Pruritus Numerical Rating Scale Of 0 Or 1 At Week 16Benzinga Newsdesk - 4 days ago
Tuesday, April 23, 2024
Sunday, April 21, 2024
Thursday, April 18, 2024
- Soon To Be Acquired Cerevel Therapeutics Reveals High Level Data From Late-Stage Parkinson's Disease StudyVandana Singh - Apr 18, 2024, 1:44PM
- AbbVie Announces Phase 3 SELECT-GCA Study Of Upadacitinib Results In Patients With Giant Cell Arteritis; In Combination With A 26-week Steroid Taper Regimen Achieved Its Primary Endpoint Of Sustained Remission; Key Secondary Endpoints Were Also MetBenzinga Newsdesk - Apr 18, 2024, 8:32AM
Wednesday, April 17, 2024
Tuesday, April 16, 2024
- Avalo Therapeutics' Newly Acquired Ex-Eli Lilly Drug Could Stand Out In Competitive Hidradenitis Suppurativa Market, Analyst UpgradesVandana Singh - Apr 16, 2024, 2:25PM
- FDA Says Counterfeit Version Of Botox Found In Multiple States; Alerting Health Care Professionals & Consumers That Unsafe Counterfeit Versions Of Botox Found In Multiple States & Administered To Consumers; Currently, There Is No Indication That The Reported Events Were Linked To Abbvie's FDA-Approved Botox; Aware Of Adverse Events, Including Hospitalizations, Linked To Counterfeit BotoxBenzinga Newsdesk - Apr 16, 2024, 9:54AM
Monday, April 15, 2024
Friday, April 12, 2024
- What's Going On AbbVie Stock On Friday?Vandana Singh - Apr 12, 2024, 2:19PM
- Smart Money Is Betting Big In ABBV OptionsBenzinga Insights - Apr 12, 2024, 10:04AM
- AbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant (QULIPTA) for Preventive Treatment of MigraineBenzinga Newsdesk - Apr 12, 2024, 7:31AM
Wednesday, April 10, 2024
Friday, April 05, 2024
Thursday, April 04, 2024
Wednesday, April 03, 2024
- AbbVie Says Q1 2024 Adj Diluted Earnings Per Share Guidance Range, Including Impact Of Q1 2024 Acquired IPR&D And Milestones Expense, Is $2.18-$2.22; Reported GAAP Earnings For Q1 Of 2024 Are Expected To Include Acquired IPR&D And Milestones Expense Of $164M On A Pre-tax BasisBenzinga Newsdesk - Apr 3, 2024, 4:27PM
- AbbVie Inc Says Adjusted Non-GAAP Earnings For Q1 Of 2024 Are Expected To Include Acquired IPR&D And Milestones Expense Of $164M On A Pre-Tax Basis; 2024 Adj Diluted EPS Guidance Range, Including Impact Of First Quarter 2024 Acquired IPR&D And Milestones Expense, Is $10.97-$11.17.Benzinga Newsdesk - Apr 3, 2024, 4:26PM
- 10 Health Care Stocks Whale Activity In Today's SessionBenzinga Insights - Apr 3, 2024, 1:35PM
- FibroGen Unveils Early Data From Prostate Cancer Candidate, Analyst Advocates Further Exploration In The LandscapeVandana Singh - Apr 3, 2024, 10:02AM
Thursday, March 28, 2024
Wednesday, March 27, 2024
Tuesday, March 26, 2024
Monday, March 25, 2024
- Nasdaq Turns Higher; Akanda Shares PlungeAvi Kapoor - Mar 25, 2024, 3:00PM
- Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day SessionAvi Kapoor - Mar 25, 2024, 2:44PM
- Crude Oil Moves Higher; US New Home Sales Fall In FebruaryAvi Kapoor - Mar 25, 2024, 11:54AM
- Why Is Ulcerative Colitis-Focused Landos Biopharma Stock Trading Higher On Monday?Vandana Singh - Mar 25, 2024, 11:27AM
- US Stocks Down; Chicago Fed National Activity Index Rises In FebruaryAvi Kapoor - Mar 25, 2024, 9:42AM
- AbbVie To Acquire Landos Biopharma At A Price Of $20.42 Per Share In Cash Upon Closing, Or ~$137.5MBenzinga Newsdesk - Mar 25, 2024, 8:32AM
Friday, March 22, 2024
- The Latest Analyst Ratings For AbbVieBenzinga Insights - Mar 22, 2024, 3:01PM
- FDA Approves Mirvetuximab Soravtansine-Gynx For FRA Positive, Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal CancerBenzinga Newsdesk - Mar 22, 2024, 2:30PM
- Guggenheim Maintains Buy on AbbVie, Raises Price Target to $190Benzinga Newsdesk - Mar 22, 2024, 2:02PM